A recent study published in Science Translational Medicine has examined a new approach to address inflammatory skin diseases, such as dermatitis and rosacea, by focusing on a specific glutamate receptor in mast cells.

Gilead Sciences Inc. and Leo Pharma A/S have established a strategic partnership to accelerate the development and commercialization of Leo’s small-molecule oral STAT6 programs for the treatment of inflammatory diseases.

Nimbus Therapeutics LLC has disclosed 15-hydroxyprostaglandin dehydrogenase inhibitors reported to be useful for the treatment of alopecia, muscle atrophy and more.

Deepcure Inc. has discovered potent, selective oral small-molecule inhibitors of STAT6. These next-generation STAT6 inhibitors have demonstrated promising oral bioavailability, cell permeability and metabolic stability, and do not target STAT6 for degradation.

Researchers from Tavotek Biotherapeutics Inc. described the discovery and preclinical characterization of TAVO-101.

Sunshine Lake Pharma Co Ltd. has divulged non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of multiple sclerosis, psoriasis, rheumatoid arthritis, atopic dermatitis, scleroderma, lupus nephritis, systemic lupus erythematosus and ulcerative colitis, among others.

Onquality Pharmaceuticals China Ltd. has synthesized prodrugs of tofacitinib acting as JAK inhibitors reported to be useful for the treatment of atopic dermatitis, psoriasis and alopecia areata.

Adimune Inc., a subsidiary of Aditxt Inc., has successfully completed preclinical studies for its antigen-specific gene therapy, ADI-100.